(Reuters) - European shares were flat in early trade on Wednesday, as gains led by healthcare stocks following drugmaker Novo ...

Danish pharmaceutical behemoth Novo Nordisk reported better-than-expected net profit in the fourth quarter, amid soaring ...

Novo Nordisk expects sales growth to slow this year as capacity constraints, intensifying competition and pricing pressure drag on sales of its blockbuster weight-loss and diabetes drugs. The Danish ...

Its a healthy morning as Novo Nordisk says sales of its obesity drug, Wegovy, rose 57% last year while Brits are buying more ...

Theme parks have been a concern for analysts, amid signs that U.S. consumer spending is on the wane.

Ozempic, which accounts for 41% of the company's sales, is an injectable anti-diabetic treatment that became wildly popular ...

Sales of Novo Nordisk’s obesity drug, Wegovy, rose by more than 50 per cent last year, helping the Danish drugmaker beat revenue expectations.

Wegovy maker Novo Nordisk has today forecast sales would grow at a slower rate this year although the outlook was roughly in ...

Adani Wilmar is expecting an around 10% growth in sales volume next fiscal year, CEO Angshu Mallick told Reuters on Wednesday ...

Wegovy maker Novo Nordisk on Wednesday forecast slower sales growth for 2025 than 2024, a blow that is likely to deepen ...